Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
Sponsor: NRG Oncology
Listed as NCT00981656, this PHASE2 trial focuses on Bladder Cancer and remains completed. Sponsored by NRG Oncology, it has been updated 14 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2023 — May 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
May 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NRG Oncology
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .